Personalized screening

April 15, 2022

Enrollment in TMIST Breast Cancer Screening Trial Surpasses Halfway Mark; Recruitment of Women from Diverse Backgrounds is Key to Success

Enrollment doubles in past 17 months due to specific efforts — Black participation rises above 20%
October 19, 2020

TMIST Breast Cancer Screening Trial Rebounds from COVID-19 Shutdown of Cancer Screenings

October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance
June 10, 2020

The Value of TMIST Compared to Other Breast Cancer Screening Studies

TMIST will provide data that is critical for relating the increased rate of detection of early breast cancers to the clinical outcomes of the screening population